Lung Cancer最新文献

{"title":"Redefining resectability: Bridging perspectives in stage III NSCLC management","authors":"Luca Bertolaccini , Monica Casiraghi , Antonio Mazzella , Lorenzo Spaggiari","doi":"10.1016/j.lungcan.2025.108509","DOIUrl":"10.1016/j.lungcan.2025.108509","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108509"},"PeriodicalIF":4.5,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-year survival and disease recurrence after endosonography with or without confirmatory mediastinoscopy for resectable lung cancer (a short communication of the MEDIASTrial follow-up)","authors":"Jelle E. Bousema ,&nbsp;Louisa N. Spaans ,&nbsp;Marcel G.W. Dijkgraaf ,&nbsp;Erik H.F.M. van der Heijden ,&nbsp;Ad F.T.M. Verhagen ,&nbsp;Jouke T. Annema ,&nbsp;Frank J.C. van den Broek","doi":"10.1016/j.lungcan.2025.108462","DOIUrl":"10.1016/j.lungcan.2025.108462","url":null,"abstract":"<div><div>Resectable non-small cell lung cancer (NSCLC) with increased risk of mediastinal nodal involvement requires invasive staging prior to surgical resection. The MEDIASTrial was a multicenter non-inferiority trial randomly assigning patients after negative endosonography to immediate lung tumor resection (n = 178) or to mediastinoscopy first (n = 182), only followed by tumor resection after negative mediastinoscopy. The omission of confirmatory mediastinoscopy after negative endosonography led to a clinically negligible and non-inferior increase in unforeseen N2.</div><div>We report the two-year overall and disease-free survival (OS and DFS) and the health-related quality-of-life (HRQoL) gathered with the QLQ-C30 and QLQ-LC13 questionnaires.</div><div>After randomization seven drop-outs were observed in both groups. Time to 80 % OS was 25 months in the immediate resection group versus 20 months in the mediastinoscopy group (adjusted HR 0.8, 95 % CI: 0.5–1.3). Time to 65 % DFS was 25 months in the immediate resection group versus 25 months in the mediastinoscopy group (adjusted HR 0.9, 95 % CI: 0.6–1.4). The HRQoL scores were comparable among the groups during the two-year follow-up.</div><div>The loss in diagnostic yield by omitting confirmatory mediastinoscopy after negative systematic endosonography has no impact on two-year OS, DFS and HRQoL in patients with resectable NSCLC and an indication for invasive mediastinal nodal staging.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108462"},"PeriodicalIF":4.5,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143697484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ex vivo drug testing of patient-derived lung organoids: The breakthrough of organotypic tissue slices for physiologically relevant imaging","authors":"V.A. Shestakova ,&nbsp;E.I. Smirnova ,&nbsp;D.S. Baranovskii ,&nbsp;I.D. Klabukov","doi":"10.1016/j.lungcan.2025.108503","DOIUrl":"10.1016/j.lungcan.2025.108503","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"203 ","pages":"Article 108503"},"PeriodicalIF":4.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the prognostic impact of EGFR mutation on adjuvant chemotherapy efficacy in grade 3 stage IB lung adenocarcinoma","authors":"Zhao An ,&nbsp;Ye Ning ,&nbsp;Jie Mei,&nbsp;Chenlu Yang,&nbsp;Xiaodong Yang","doi":"10.1016/j.lungcan.2025.108507","DOIUrl":"10.1016/j.lungcan.2025.108507","url":null,"abstract":"<div><h3>Objectives</h3><div>Adjuvant chemotherapy (ACT) for patients with stage IB lung adenocarcinoma (LUAD) is controversial, particularly in those with epidermal growth factor receptor (EGFR) mutations. This study aims to evaluate the efficacy of ACT in stage IB LUAD with Grade 3 and explore the prognostic impact of EGFR mutations status on chemotherapy effectiveness.</div></div><div><h3>Methods</h3><div>We identified 707 high-risk (Grade 3) stage IB LUAD patients who underwent complete resection between 2014 and 2018. The Kaplan-Meier curves was used to assess recurrence-free survival (RFS) and overall survival (OS). Prognostic factors were evaluated using the Cox proportional hazards model, and propensity score matching was applied to reduce bias from confounding variables.</div></div><div><h3>Results</h3><div>In the entire cohort, patients who received ACT showed significantly better 5-year RFS and OS compared to those who did not (P &lt; 0.001 for both). Among 247 patients without EGFR mutations, 125 (50.6 %) received ACT and 122 (49.4 %) did not. In the propensity score-matched cohort of 84 pairs, those treated with ACT had significantly better 5-year RFS and OS (P &lt; 0.01 for both). Among 460 patients with EGFR mutations, 237 (51.5 %) received ACT and 223 (48.5 %) did not. In the matched cohort of 184 pairs, ACT recipients had significantly better prognoses. Multivariable analysis confirmed ACT was an independent prognostic factor, while EGFR mutation status was not.</div></div><div><h3>Conclusions</h3><div>ACT significantly improves the prognosis of patients with Grade 3 stage IB LUAD, irrespective of EGFR mutation status. These findings support the clinical adoption of ACT for this patient subgroup.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108507"},"PeriodicalIF":4.5,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors","authors":"Kazuya Takamochi ,&nbsp;Kenji Suzuki ,&nbsp;Morihito Okada ,&nbsp;Seiji Niho ,&nbsp;Satoshi Ishikura ,&nbsp;Shunsuke Oyamada ,&nbsp;Takuhiro Yamaguchi ,&nbsp;Hirotoshi Horio ,&nbsp;Norihiko Ikeda ,&nbsp;Fumihiro Tanaka ,&nbsp;Satoshi Shiono ,&nbsp;Tomohiro Haruki ,&nbsp;Ichiro Yoshino ,&nbsp;Hiroyuki Ito ,&nbsp;Hidetaka Uramoto ,&nbsp;Norihito Okumura ,&nbsp;Hisashi Iwata ,&nbsp;Hisashi Saji ,&nbsp;Toshiya Fujiwara ,&nbsp;Kazuhito Funai ,&nbsp;Masahiro Tsuboi","doi":"10.1016/j.lungcan.2025.108506","DOIUrl":"10.1016/j.lungcan.2025.108506","url":null,"abstract":"<div><h3>Purpose</h3><div>This multicenter single-arm confirmatory trial (CRES³T) investigated the efficacy and safety of S-1 + cisplatin and concurrent radical-dose radiotherapy followed by surgery in patients with a superior sulcus tumor.</div></div><div><h3>Methods</h3><div>Patients received induction therapy comprising three cycles of S-1 + cisplatin with concurrent radiotherapy (66 Gy in 33 fractions) followed by surgery. S-1 was administered orally at 40 mg/m² twice/day on days 1–14, with an intravenous infusion of cisplatin (60 mg/m²) on day 1. The primary endpoint was the 3-year overall survival rate; key secondary endpoints included progression-free survival rate, objective response rate, pathological complete response rate, and toxicity.</div></div><div><h3>Results</h3><div>Sixty-one patients with a superior sulcus non-small cell lung cancer received induction therapy. Radiological tumor invasion sites were the chest wall (n = 57), subclavian artery (n = 18), and subclavian vein (n = 10). Forty-nine patients underwent a lobectomy and combined resection of the involved structures. The objective and pathological complete response rates were 42 % (95 % confidence interval: 29–54 %) and 33 % (95 % confidence interval: 20–46 %), respectively. The 3-year overall survival and progression-free survival rates were 73.2 % (95 % confidence interval: 60.1–82.7 %) and 53.3 % (95 % confidence interval: 40.0–65.0 %), respectively. The patterns of first tumor relapse were locoregional only in one, distant metastasis only in 18, and both in four patients. Two pneumonia cases during induction therapy and one cardiac-arrest case on postoperative day 3 resulted in death.</div></div><div><h3>Conclusions</h3><div>Induction therapy using S-1 + cisplatin and concurrent radical-dose radiotherapy followed by surgery maximized local control and improved overall survival without impairing safety, potentially representing a new standard treatment.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108506"},"PeriodicalIF":4.5,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention","authors":"Kari Hemminki ,&nbsp;Frantisek Zitricky ,&nbsp;Kristina Sundquist ,&nbsp;Jan Sundquist ,&nbsp;Asta Försti ,&nbsp;Akseli Hemminki","doi":"10.1016/j.lungcan.2025.108500","DOIUrl":"10.1016/j.lungcan.2025.108500","url":null,"abstract":"<div><h3>Introduction</h3><div>Familial risk of lung cancer (LC) is at the level of many common cancers (ca 2.0) but as cigarette smoking is the main cause of LC, it has remained undefined to what extent smoking contributes to the familial risk. We take advantage of the natural experiment of divorce. In Sweden, it has been customary that children stay with their mother after divorce. We thus hypothesize that only maternal half-siblings share the childhood environment to the same extent than full siblings.</div></div><div><h3>Methods</h3><div>We used Swedish nation-wide data on family structures and cancers up to year 2021 to determined LC risk (standardized incidence ratio, SIR with 95% confidence intervals) in maternal and paternal half-siblings and in full siblings.</div></div><div><h3>Results</h3><div>Familial risk for LC in maternal half-siblings was 2.21 (1.76–2.77) which was not different from that of full siblings 2.23 (2.22–2.44). For paternal half-siblings the risk was 1.56 (1.21–2.01). For adenocarcinoma the risks were for full siblings 2.36 (2.23–2.51), for maternal half-siblings 2.55 (1.93–3.35) and for paternal half-siblings 1.33 (0.94–1.87).</div></div><div><h3>Conclusions</h3><div>The results showed that familial risk for LC was equal in full siblings and in maternal half-siblings; the risks for paternal half-siblings were lower and for adenocarcinoma significantly lower than those for full siblings. The results suggest that smoking is a major contributor to familial risk of LC in this setting. Smoking starts at an early age and anti-smoking campaigns should target childhood environment for prevention of smoking initiation.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108500"},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The diagnostic value of comprehensive next-generation sequencing for genetic mutations in suspected lung cancer cases with negative pathological cytology","authors":"Yuka Goto ,&nbsp;Satoshi Watanabe ,&nbsp;Naohiro Yanagimura ,&nbsp;Masashi Arita ,&nbsp;Miyuki Sato ,&nbsp;Koichiro Nozaki ,&nbsp;Tomohiro Tanaka ,&nbsp;Yu Saida ,&nbsp;Makoto Maemondo ,&nbsp;Kunihiko Kobayashi ,&nbsp;Koichi Hagiwara ,&nbsp;Toshiaki Kikuchi","doi":"10.1016/j.lungcan.2025.108505","DOIUrl":"10.1016/j.lungcan.2025.108505","url":null,"abstract":"<div><h3>Introduction</h3><div>In recent clinical practice, driver gene mutations have been tested using multiplex PCR or next-generation sequencing (NGS), which help determine treatment strategies for non-small cell lung cancer (NSCLC). We developed a new analysis system, the Mutation Investigator using Next-era Sequencer (MINtS), using NGS, which allows for the detection of gene mutations even in cytology specimens with low tumor cell content. Due to its high sensitivity, MINtS has the potential to detect gene mutations even in specimens that are pathologically negative for cancer. In the present study, we examined the utility of MINtS-based mutation detection in cytology-negative specimens.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed the data of patients who were enrolled in the NEJ021A study, which was a prospective observational study investigating the performance of MINtS. Although NEJ021A was a multicenter study, we included only patients enrolled at Niigata University Medical and Dental Hospital.</div></div><div><h3>Results</h3><div>Cytology specimens from 486 patients with suspected lung cancer were analyzed using MINtS. Among the cytology-positive cases, driver gene mutations were detected in 37.3 % (93/249) of patients, whereas in cytology-negative cases, driver gene mutations were detected in 20.2 % (47/233) of patients using MINtS. Of the 47 patients whose specimens were cytology-negative and MINtS-positive, 42 were histologically or clinically diagnosed with NSCLC and received treatment.</div></div><div><h3>Conclusions</h3><div>Even in patients without a pathological diagnosis of lung cancer, MINtS can identify driver gene mutations, which can be useful for guiding subsequent treatment decisions.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108505"},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exclusive radiologically determined myopenia does not equate to sarcopenia","authors":"Erkan Topkan ,&nbsp;Ugur Selek","doi":"10.1016/j.lungcan.2025.108504","DOIUrl":"10.1016/j.lungcan.2025.108504","url":null,"abstract":"","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108504"},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143674255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Feasibility and safety of perioperative entrectinib in a patient with ROS1-positive locally advanced NSCLC: A case report","authors":"Mengying Fan ,&nbsp;Wanpu Yan ,&nbsp;Minglei Zhuo ,&nbsp;Rong Yu ,&nbsp;Liping Qi ,&nbsp;Xin Yang ,&nbsp;Yifan Fang ,&nbsp;Ke-Neng Chen","doi":"10.1016/j.lungcan.2025.108501","DOIUrl":"10.1016/j.lungcan.2025.108501","url":null,"abstract":"<div><div>NSCLC with <em>ROS1</em> fusion mutations represents a rare mutation subtype, making it challenging to conduct randomized controlled studies. Here, we report the case of a patient with stage IIIA (cT2aN2M0) <em>ROS1</em> fusion lung adenocarcinoma who achieved downstaging and completed resection after a 3-month treatment with entrectinib, resulting in a postoperative pathological stage of ypT1cN0M0. The patient continued adjuvant entrectinib therapy and has remained recurrence-free during follow-up, with 21 months since diagnosis and 18 months since surgery.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108501"},"PeriodicalIF":4.5,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143683200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of antiangiogenic therapy in patients with advanced SMARCA4-deficient thoracic tumor","authors":"Mengting Shi ,&nbsp;Xueyuan Chen ,&nbsp;Ting Lin ,&nbsp;Jinhui Xue ,&nbsp;Yuanyuan Zhao ,&nbsp;Zhixiong Lin","doi":"10.1016/j.lungcan.2025.108498","DOIUrl":"10.1016/j.lungcan.2025.108498","url":null,"abstract":"<div><h3>Background</h3><div>SMARCA4 (BRG1)-deficient thoracic tumors (SDTTs) are frequently diagnosed at an advanced stage and had poor prognosis, underscoring the critical importance of seeking out novel therapeutic avenues, particularly in the realm of antiangiogenic treatment. However, the efficacy of antiangiogenic therapy in SDTT remains unknown.</div></div><div><h3>Method</h3><div>We conducted a retrospective cohort study at SYSUCC from August 1, 2018, to August 15, 2024, screening patients diagnosed with advanced SDTTs confirmed by immunohistochemistry.</div></div><div><h3>Results</h3><div>A total of 151 patients with advanced SDTTs were enrolled in the study, including 49 patients received anti-angiogenic therapy and 102 patients never. The ORR and DCR of first-line therapy with antiangiogenic therapy was 51.4 % and 86.5 %, respectively, compared to only 37.1 % and 78.7 % for those without antiangiogenic therapy. The median PFS of SDTTs treated with antiangiogenic therapy was significantly longer than those without (7.97vs.5.87 months, HR [95 %CI]: 0.612[0.380–0.984], <em>P</em> = 0.043). For patients who did not receive immune checkpoint inhibitors (ICIs), the median PFS of SDTTs treated with anti-angiogenic agent combined with chemotherapy (C + A) was longer than those treated with chemotherapy alone (C) (5.10 vs 2.57 months, HR [95 %CI]: 0.365[0.137–0.968], <em>P</em> = 0.043). For patients received chemotherapy and ICIs, the addition of anti-angiogenic agent (C + I + A) provided significantly longer PFS (11.90 vs 6.90 months, HR [95 %CI]:0.425, [0.221–0.818], <em>P</em> = 0.010). This C + I + A therapy outperforms C + A therapy, showing the longest PFS (11.90 vs 5.10 months, HR [95 %CI]:0.294[0.112–0.772], <em>P</em> = 0.013).</div></div><div><h3>Conclusion</h3><div>The administration of antiangiogenic therapy shows a promising effect in first-line therapies for advanced SDTT patients. The C + I + A combination therapy is the optimal solution among currently available treatment options.</div></div>","PeriodicalId":18129,"journal":{"name":"Lung Cancer","volume":"202 ","pages":"Article 108498"},"PeriodicalIF":4.5,"publicationDate":"2025-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143643504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}